Investors Business Daily EN

Uniqure Plummets As FDA's Marty Makary Disparages Rejected Rare Disease Drug

Uniqure stock plummeted Thursday after Marty Makary appeared on CNBC to defend the FDA's recent rejections of rare disease drugs. The post Uniqure Plummets As FDA's Marty Makary Disparages Rejected Rare Disease Drug appeared first on Investor's Business Daily.

Feb 26, 2026 &02352626202628; 17:35 UTC www.investors.com

Read original on www.investors.com ↗

↘

Negative for markets

Sentiment score: -100/100

High impact Immediate effect (hours)

WHAT THIS MEANS

Le azioni di Uniqure subiscono un forte crollo dopo le dichiarazioni del funzionario FDA Marty Makary su CNBC, che ha difeso il recente rifiuto dei farmaci per malattie rare. L'evento evidenzia la continua pressione normativa sul settore biotecnologico.

AI CONFIDENCE

0% Low

SENTIMENT GAUGE

NEWS POWER SCORE

AFFECTED ASSETS

↓

QURE

QUREStock

Expected to decline

Reazione negativa del mercato alle dichiarazioni del funzionario FDA che difendono il rifiuto del farmaco per malattie rare, aumentando le preoccupazioni normative

PRICE HISTORY

Loading chart...

⚡ SUGGESTED ACTION

Evitare posizioni lunghe su Uniqure nel breve termine; monitorare le successive comunicazioni della FDA per valutare eventuali opportunità di ingresso a livelli di supporto.

KEY SIGNALS

Rifiuto FDA per farmaci malattie rareDichiarazioni pubbliche di funzionario FDA su CNBCForte reazione negativa del mercato

SECTORS INVOLVED

biotecnologiefarmaceutico

Analysis generated on Feb 26, 2026 at 22:56 UTC

Disclaimer: This analysis is generated by artificial intelligence for informational purposes only and does not constitute financial advice, investment recommendation, or solicitation. Original reporting by Investors Business Daily. Always conduct your own research and consult a qualified financial advisor before making investment decisions.

Uniqure Plummets As FDA's Marty Makary Disparages Rejected Rare Disease Drug

RELATED INTELLIGENCE